Sun Pharmaceutical issued a voluntary recall of lisdexamfetamine dimesylate capsules, used for attention deficit-hyperactivity disorder (ADHD), after failing dissolution tests, the FDA said.
A randomized trial showed that message-based therapy, using emails, texts, or voice or video messages, was as effective as video-based therapy for depression. (JAMA Network Open)
A 44-trial meta-analysis showed that cognitive behavioral therapy, behavioral activation, and interpersonal therapy may be effective in the treatment of perinatal depression. (Annals of Internal Medicine)
Postpartum psychosis is a distinct mental illness within the bipolar spectrum and should be classified as such, an expert panel argued. (Biological Psychiatry)
Adolescents who attended psychiatric services and used the commonly prescribed antibiotic doxycycline may have a lower risk for developing schizophrenia over the next 10 years, according to an emulated target trial. (American Journal of Psychiatry)
People with schizophrenia, bipolar disorder, or major depression may be at increased risk for long COVID, a large U.S. cohort study suggested. (JAMA Network Open)
Avoidant/restrictive food intake disorder, or ARFID, is becoming more widely recognized among kids. (Scientific American)
Doctors and nurses in Montana filed a class-action lawsuit against a national company that runs an addiction recovery program for healthcare professionals. (Montana Free Press via AP)
“Given the sharp increase in consumer interest and the lack of generalizable research on naturally occurring psilocybin mushrooms, it is critical that the scientific community and funding agencies pivot from a narrow focus on clinical trials of synthetic psilocybin to the study of real-world psilocybin use and treat this shift as a public health priority,” authors of a JAMA Psychiatry communication wrote.
A birth cohort study linked teen cannabis use to a higher utilization of care for mental and physical health problems in young adulthood. (JAMA Network Open)
